Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: Response to albuterol, isoproterenol, and placebo aerosols☆,☆☆
References (18)
- et al.
Dynamic and static lung volumes, and blood-gas tensions in bronchial asthma
Lancet
(1969) Asthma induced by adrenergic aerosols
J. Allergy
(1970)Adverse effects of inhalation of excessive amounts of nebulized isoproterenol in status asthmaticus
J. Allergy
(1969)- et al.
Isoprenaline resistance and the use of pressurized aerosols in asthma
Lancet
(1968) - et al.
The heterogeneity of asthmatic patients—an individualized approach to diagnosis and treatment
J. Allergy Clin. Immunol
(1976) - et al.
Salbutamol and isoproterenol: a double-blind trial to compare bronchodilator and cardiovascular activity
N. Engl. J. Med
(1969) - et al.
Albuterol and isoproterenol aerosols. a controlled study of duration of effect in asthmatic patients
J. A. M. A
(1972) - et al.
Effects of salbutamol and isoprenaline/phenylephrine in reversible airways obstruction
Br. Med. J
(1972) - et al.
Comparison of varying doses of albuterol and placebo aerosols for the relief of bronchospasm
J. Allergy Clin. Immunol
(1972)
Cited by (20)
Cardiovascular risks associated with β-agonist therapy [3]
2005, ChestCitation Excerpt :The study by Pearlman et al18 included three groups and hence 67 patients rather than 46 patients in the β-agonist treatment. The studies by Spector and Garza Gomez17 and Anderson et al19 included two β-agonist treatments rather than one, and, hence, the study groups should have been twice the number reported. The study by Nathan et al20 included only the data from the salmeterol group (4 of 369 patients), not the data for the albuterol group, and, most importantly, it improperly stated that the placebo rate was 0 of 187 patients, although this was not the information presented in the article.
Cardiovascular effects of β-agonists in patients with asthma and COPD: A meta-analysis
2004, ChestCitation Excerpt :There were a total of 232 participants, with a mean age of 56.6 years. Of the longer duration trials, 14 were of asthma and 6 were of COPD.36–55 There was a total of 6,623 participants with a mean age of 52.2 years in these trials, which ranged in duration from 3 days to 1 year with a mean trial duration of 4.7 months.
The effect of albuterol aerosol on fine-motor performance in children with chronic asthma
1990, The Journal of Allergy and Clinical ImmunologyComparison of inhaled albuterol powder and aerosol in asthma
1987, The Journal of Allergy and Clinical ImmunologyBitolterol and albuterol metered-dose aerosols: Comparison of two long-acting beta<inf>2</inf>-adrenergic bronchodilators for treatment of asthma
1985, The Journal of Allergy and Clinical Immunology
- ☆
Supported in part by Allergic Disease Center Grant No. AI-10398.
- ☆☆
Presented in part at the American Academy of Allergy Thirty-second Annual Meeting, March 8 to 10, 1976, San Juan, Puerto Rico.